BioSpace News Archive

PDUFA Target Action Date of June 5, 2021 for Ryplazim ® (plasminogen) BLA Submission Ryplazim ® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early December Changes to Board of Directors OXER1 Antagonist Preclinical R&D Program Acquired New Appointments to Board of Directors

Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021 Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020. Natas

Relay & Fio joint venture, Fionet Rapid Response Group, announce over $500,000 CAD in initial contracts Fionet is a first-of-its-kind mobile testing & tracking platform designed to administer widespread rapid testing, for infectious diseases including COVID-19, and capture real-time data & insights FRR has begun platform configuration with COVID-19 rapid diagnostic tests from Abbott,

DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental Solutions Company, today announced that it will participate in the 2020 Wolfe Research Virtual Healthcare Conference on November 19th. Don Casey, Chief Executive Officer, will represent the company and his fireside chat is scheduled at 1:45PM Eastern Time. Investors and other interested parties will be able to access a live audio webcast by visiting www.dentsplysirona.com .

Guerbet a global leader in medical imaging, announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and nine months ended September 30, 2020. Results are presented in Canadian dollars unless otherwise noted. “Combatting the recent surge in COVID-19 cases is the top priority for our organization,” said President and Chief Executive Officer, Dr. Michael Guerriere. “We have learned a lot from our experience with COVID-19 and have applied these l

Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan in late-breaking presentation at 2020 EORTC-NCI-AACR Annual Symposium Phase 1b randomized, controlled trial in patients with p53-mutated advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy projected to start in the second quarter of 2021

Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced that it has closed a $42.5 million Series E equity financing.

CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”), today announced financial and operating results for the three months ended September 30, 2020.